Zhao Longmei, Zhou Shasha, Wang SiWei, Wu Rui, Meng Qingliang, Li Zhenbin, Peng Jiangyun, Liu Ying, Lu Min, Li Ming, Zhu Caifeng, Sun Yue, He Yanlin, Jin Yue, Gao Jingyue, Zhang Shumin, Li Peihao, Liao Rongjun, Liu Wei, Zhang Guoming
Ordos Traditional Chinese Medicine Hospital, Ordos, 017010, Inner Mongolia, China.
Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China.
Chin Med. 2024 Jan 25;19(1):18. doi: 10.1186/s13020-024-00880-7.
In Traditional Chinese Medicine (TCM) theory, cold dampness obstruction is one of the common syndromes of osteoarthritis. Therefore, in clinical practice, the main treatment methods are to dispel wind, remove dampness, and dissipate cold, used to treat knee osteoarthritis (KOA). This report describes a mulitercenter clinical study to assess Zhuifeng Tougu Capsule's efficacy and safety in the treatment of patients who are cold dampness obstruction syndrome in KOA, and to provide evidence-based medical for the rational use of Zhuifeng Tougu Capsules in clinical practice.
This randomized, parallel group controlled, double-blind, double dummy trial will include a total of 215 KOA patients who meet the study criteria. 215 patients underwent 1:1 randomisation, with 107 cases assigned the experimental group (Zhuifeng Tougu Capsules + Glucosamine Sulfate Capsules Simulator) and 108 assigned the control group (Glucosamine Sulfate Capsules + Zhuifeng Tougu Capsules Simulator). After enrolment, patients received 12 weeks of treatment. The main efficacy measure is the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain score. Visual analogue scale (VAS) pain score, Self-condition assessment VAS score, WOMAC KOA score, TCM syndrome score and TCM syndrome efficacy, ESR level, CRP level, suprapatellar bursa effusion depth, use of rescue drugs, and safety indicators are secondary efficacy indicators.
Compared with before treatment, WOMAC pain score, VAS pain score, Self-condition assessment VAS score, WOMAC KOA score, and TCM syndrome score decreased significantly in both groups (P < 0.01). Also, the experimental group showed significant differences in the above indicators compared to control (P < 0.01). However, after treatment, no significant differences were showed in the ESR level, CRP level, and suprapatellar bursa effusion depth between the two groups (P > 0.05). No any serious adverse effects showed in the experimental group and control group.
Zhuifeng Tougu Capsules can effectively improve knee joint function and significantly alleviate the pain of KOA.
Clinical trial registration was completed with the China Clinical Trial Registration Center for this research protocol (No. ChiCTR2000028750) on January 2, 2020.
在中医理论中,寒湿痹阻是骨关节炎常见证候之一。因此,在临床实践中,主要治疗方法是祛风、除湿、散寒,用于治疗膝关节骨关节炎(KOA)。本报告描述了一项多中心临床研究,以评估追风透骨胶囊治疗KOA寒湿痹阻证患者的疗效和安全性,并为临床合理使用追风透骨胶囊提供循证医学依据。
本随机、平行组对照、双盲、双模拟试验共纳入215例符合研究标准的KOA患者。215例患者按1:1随机分组,107例分配至试验组(追风透骨胶囊+硫酸氨基葡萄糖胶囊模拟剂),108例分配至对照组(硫酸氨基葡萄糖胶囊+追风透骨胶囊模拟剂)。入组后,患者接受12周治疗。主要疗效指标为西安大略和麦克马斯特大学骨关节炎指数(WOMAC)疼痛评分。视觉模拟量表(VAS)疼痛评分、自我病情评估VAS评分、WOMAC KOA评分、中医证候评分及中医证候疗效、血沉水平、C反应蛋白水平、髌上囊积液深度、急救药物使用情况及安全性指标为次要疗效指标。
与治疗前相比,两组WOMAC疼痛评分、VAS疼痛评分、自我病情评估VAS评分、WOMAC KOA评分及中医证候评分均显著降低(P<0.01)。此外,试验组上述指标与对照组相比差异有统计学意义(P<0.01)。然而,治疗后两组血沉水平、C反应蛋白水平及髌上囊积液深度比较,差异无统计学意义(P>0.05)。试验组和对照组均未出现任何严重不良反应。
追风透骨胶囊能有效改善膝关节功能,显著减轻KOA疼痛。
本研究方案于2020年1月2日在中国临床试验注册中心完成临床试验注册(注册号:ChiCTR2000028750)。